Effect of introducing high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children
This is the main finding of a recent article based on data from The Streptococcus pneumoniae Invasive Disease network (SpIDnet).
Surveillance of invasive pneumococcal disease in Europe
Decline in early childhood respiratory tract infections in the norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination
The study design and analysis controlled for influence of potentially confounding trends, such as improvement of day-care carriage and decreasing prevalence of smoking during the study period.
Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children
The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.
Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France
This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate VaccineArchived
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
Paediatric pneumococcal disease in Central EuropeArchived
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.